Think Tank on TROP-2 Therapy in NSCLC: A Look to the Future

Get up to date on emerging TROP-2–targeted antibody–drug conjugates for the treatment of advanced NSCLC with this comprehensive educational program, including expert-authored commentaries, a text module with a downloadable slideset capturing a panel discussion among 5 lung cancer experts, and a guided infographic on adverse event management with these agents.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.